Safety and efficacy of azacitidine in myelodysplastic syndromes

被引：25
|
作者：
Vigil, Carlos E. [1 ]
Martin-Santos, Taida [1 ]
Garcia-Manero, Guillermo [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit 428, Houston, TX 77030 USA
来源：
DRUG DESIGN DEVELOPMENT AND THERAPY | 2010年 / 4卷
关键词：
Azacitidine; MDS; hypomethylating agents; MYELOID-LEUKEMIA; VALPROIC ACID; 5-AZACYTIDINE; TRANSPLANTATION; EXPRESSION; 5-AZA-2'-DEOXYCYTIDINE; METHYLATION; COMBINATION; ANTIGENS; CANCER;
D O I：
10.2147/DDDT.S3143
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Purpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed. Summary: Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 75 mg/m(2) daily for 7 days, with different treatment schedules validated. It appears to be well tolerated, with the most common adverse effects being myelosuppression. Several other off-label recommendations were also analyzed. Conclusion: Azacitidine is the first DNA hypomethylating agent approved by FDA for the treatment of myelodysplastic syndromes with demonstrated efficacy.
引用
收藏
页码：221 / 229
页数：9
相关论文
共 50 条
  • [1] Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes
    Navada, Shyamala C.
    Silverman, Lewis R.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2017, 8 (01) : 21 - 27
  • [2] Azacitidine - In myelodysplastic syndromes
    Siddiqui, MAA
    Scott, LJ
    DRUGS, 2005, 65 (13) : 1781 - 1789
  • [3] Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes
    Santini, Valeria
    EXPERT REVIEW OF HEMATOLOGY, 2009, 2 (02) : 121 - 127
  • [4] Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes
    Chou, Wen-Chien
    Yeh, Su-Peng
    Hsiao, Liang-Tsai
    Lin, Sheng-Fung
    Chen, Yeu-Chin
    Chen, Tsai-Yun
    Laille, Eric
    Galettis, Anoula
    Dong, Qian
    Songer, Steve
    Beach, C. L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) : E430 - E439
  • [5] Azacitidine in myelodysplastic syndromes - A viewpoint
    Santini, V
    DRUGS, 2005, 65 (13) : 1790 - 1790
  • [6] Efficacy and safety of deferasirox in myelodysplastic syndromes
    Breccia, Massimo
    Alimena, Giuliana
    ANNALS OF HEMATOLOGY, 2013, 92 (07) : 863 - 870
  • [7] Efficacy and safety of deferasirox in myelodysplastic syndromes
    Massimo Breccia
    Giuliana Alimena
    Annals of Hematology, 2013, 92 : 863 - 870
  • [8] Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes
    Fujimaki, Katsumichi
    Miyashita, Kazuho
    Kawasaki, Rika
    Tomita, Naoto
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 97 (03) : 228 - 231
  • [9] Efficacy and Safety of a 5-Day Regimen of Azacitidine for Patients with High-Risk Myelodysplastic Syndromes
    Fujimaki, Katsumichi
    Miyashita, Kazuho
    Kawasaki, Rika
    Tomita, Naoto
    Ishigatsubo, Yoshiaki
    BLOOD, 2014, 124 (21)
  • [10] Efficacy of azacitidine for TP53-mutated myelodysplastic syndromes (MDS).
    Nannya, Yasuhito
    Takeda, June
    Sato, Shinya
    Shiraishi, Yuichi
    Yoshida, Kenichi
    Shiozawa, Yusuke
    Makishima, Hideki
    Nakao, Shinji
    Ohyashiki, Kazuma
    Miyazaki, Yasushi
    Naoe, Tomoki
    Miyano, Satoru
    Ogawa, Seishi
    CANCER SCIENCE, 2018, 109 : 423 - 423
12345